Preventing cancer spread in breast cancer patients after treatment.
Targeting the HMGB1-TLR5 pathway to prevent senescence-induced metastasis in breast cancer.
This study is looking at how some breast cancer treatments, like chemotherapy, might accidentally help cancer cells spread, and it aims to find ways to stop this from happening so that patients can have better outcomes after their initial treatment.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10877893 on NIH RePORTER |
What this research studies
This research investigates how certain treatments for breast cancer, like chemotherapy, can unintentionally lead to the spread of cancer cells. It focuses on understanding the biological processes that occur when cancer cells and surrounding healthy cells respond to treatment, particularly how they can become more aggressive. By targeting specific pathways involved in this process, the research aims to develop strategies to prevent the spread of cancer after initial treatment, potentially improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients undergoing chemotherapy or radiotherapy who are at risk of metastasis.
Not a fit: Patients with non-breast cancers or those not receiving chemotherapy or radiotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent the spread of breast cancer after chemotherapy, improving survival rates.
How similar studies have performed: Other research has shown promise in targeting similar pathways to reduce cancer metastasis, indicating that this approach may be effective.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: David, Gregory — New York University School of Medicine
- Study coordinator: David, Gregory
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.